Alzheimer's Research Pivots to Multi-Target Strategies After Amyloid Limits Emerge

The field is moving beyond single-mechanism amyloid-clearing drugs. Of 171 ongoing studies in the pipeline, candidates now target tau aggregation, neuroinflammation, and synaptic loss—a shift mirroring HIV's evolution from monotherapy to combination regimens. Early FDA approvals in 2024 slowed cognitive decline by 29% but failed to halt progression, exposing amyloid's insufficiency. The diversification reflects growing confidence in druggable targets and reflects recognition that complex neurodegenerative disease requires multi-modal intervention.